Several studies have demonstrated that anti-EGFR antibodies such as Cetuximab and Panitumumab, coupled with near infrared (NIR) fluorescent dyes IRDye 800CW, allowed a better identification of tumor margins during FGS and improved an ex-vivo analysis of specimens [12, 13, 15, 16]. Here, EGFR is linked to neoplasm.